News stories about Omeros (NASDAQ:OMER) have been trending somewhat positive on Thursday, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Omeros earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.1937679989377 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Analysts’ Ratings for Omeros and Peers in March 2018 (finance.yahoo.com)
- A Look at Omeros’s Promising Research Pipeline (finance.yahoo.com)
- Why Omeros’s Revenue Surged (finance.yahoo.com)
- What’s behind Omeros’s Cash Flow (finance.yahoo.com)
- Omeros Corporation (OMER) – New 52-Week High Stock in Focus (thestocksnews.com)
Shares of NASDAQ:OMER traded down $0.74 during midday trading on Thursday, hitting $11.17. 839,199 shares of the stock were exchanged, compared to its average volume of 1,383,595. Omeros has a 52-week low of $8.36 and a 52-week high of $27.09. The firm has a market cap of $591.02, a P/E ratio of -9.55 and a beta of 3.57. The company has a quick ratio of 4.10, a current ratio of 4.12 and a debt-to-equity ratio of -29.93.
Several brokerages recently weighed in on OMER. Maxim Group set a $24.00 price objective on Omeros and gave the stock a “buy” rating in a research report on Monday, January 22nd. Wedbush lowered Omeros from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $47.00 to $19.00 in a research report on Friday, March 23rd. HC Wainwright set a $30.00 price objective on Omeros and gave the stock a “buy” rating in a research report on Wednesday, November 29th. ValuEngine lowered Omeros from a “sell” rating to a “strong sell” rating in a research report on Friday, February 23rd. Finally, Needham & Company LLC lowered Omeros from a “buy” rating to a “hold” rating and set a $9.01 price target for the company. in a research report on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $25.88.
TRADEMARK VIOLATION WARNING: This piece was first published by BBNS and is the property of of BBNS. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/03/30/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-omeros-omer-stock-price/1973384.html.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.